Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdb48577f62fd97bad781d9ca6a562fe |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0273 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015 |
filingDate |
2016-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fe46a586b6cffe4a9c10b1b03f5b2af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed615fe04513454b2c0a09ac355050bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74b339efd078965c6ad81e3fe9ff4132 |
publicationDate |
2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018049459-A1 |
titleOfInvention |
Vaccine comprising drug and parasite administration |
abstract |
Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022236370-A1 |
priorityDate |
2016-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |